Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays

por Bièche, I, Olivi, M, Noguès, C, Vidaud, M, Lidereau, R
Publicado 2002

KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition

por Rouleau, E, Spyratos, F, Dieumegard, B, Guinebretière, J M, Lidereau, R, Bièche, I
Publicado 2008

Prognostic value of maspin mRNA expression in ERα-positive postmenopausal breast carcinomas

por Bièche, I, Girault, I, Sabourin, J-C, Tozlu, S, Driouch, K, Vidaud, M, Lidereau, R
Publicado 2003

Overexpression of the stathmin gene in a subset of human breast cancer.

por Bièche, I., Lachkar, S., Becette, V., Cifuentes-Diaz, C., Sobel, A., Lidereau, R., Curmi, P. A.
Publicado 1998

Gene expression and hepatitis C virus infection

por Asselah, T, Bièche, I, Sabbagh, A, Bedossa, P, Moreau, R, Valla, D, Vidaud, M, Marcellin, P
Publicado 2009

Epigenetic inactivation of SLIT3 and SLIT1 genes in human cancers

por Dickinson, R E, Dallol, A, Bieche, I, Krex, D, Morton, D, Maher, E R, Latif, F
Publicado 2004

Hedgehog pathway activation in human transitional cell carcinoma of the bladder

por Pignot, G, Vieillefond, A, Vacher, S, Zerbib, M, Debre, B, Lidereau, R, Amsellem-Ouazana, D, Bieche, I
Publicado 2012

Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours

por Curmi, P A, Noguès, C, Lachkar, S, Carelle, N, Gonthier, M-P, Sobel, A, Lidereau, R, Bièche, I
Publicado 2000

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity

por Serova, M, Bieche, I, Sablin, M-P, Pronk, G J, Vidaud, M, Cvitkovic, E, Faivre, S, Raymond, E
Publicado 2011

ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels

por Rondeau, S, Vacher, S, De Koning, L, Briaux, A, Schnitzler, A, Chemlali, W, Callens, C, Lidereau, R, Bièche, I
Publicado 2015

CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients

por Lefort, S, Thuleau, A, Kieffer, Y, Sirven, P, Bieche, I, Marangoni, E, Vincent-Salomon, A, Mechta-Grigoriou, F
Publicado 2017

RASSF2 can suppress the growth of breast cancer cell lines and is epigenetically inactivated in breast tumours

por Cooper, WN, Dickinson, RE, Dallol, A, Hesson, LB, Bieche, I, Clark, GJ, Maher, ER, Zabarovsky, ER, Latif, F
Publicado 2008

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab

por Cizkova, M, Dujaric, M-E, Lehmann-Che, J, Scott, V, Tembo, O, Asselain, B, Pierga, J-Y, Marty, M, de Cremoux, P, Spyratos, F, Bieche, I
Publicado 2013

A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation

por Weiswald, L-B, Richon, S, Massonnet, G, Guinebretière, J-M, Vacher, S, Laurendeau, I, Cottu, P, Marangoni, E, Nemati, F, Validire, P, Bellet, D, Bièche, I, Dangles-Marie, V
Publicado 2013

Tumor BRCA testing can reveal a high tumor mutational burden related to POLE pathogenic variants

por Villy, M.-C., Masliah-Planchon, J., Melaabi, S., Trabelsi Grati, O., Girard, E., Bataillon, G., Vincent-Salomon, A., Le Gall, J., Golmard, L., Stoppa-Lyonnet, D., Bieche, I., Colas, C.
Publicado 2021

Clinical value of R-spondins in triple-negative and metaplastic breast cancers

por Coussy, F, Lallemand, F, Vacher, S, Schnitzler, A, Chemlali, W, Caly, M, Nicolas, A, Richon, S, Meseure, D, El Botty, R, De-Plater, L, Fuhrmann, L, Dubois, T, Roman-Roman, S, Dangles-Marie, V, Marangoni, E, Bièche, I
Publicado 2017

Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness

por Weiswald, L-B, Richon, S, Validire, P, Briffod, M, Lai-Kuen, R, Cordelières, F P, Bertrand, F, Dargere, D, Massonnet, G, Marangoni, E, Gayet, B, Pocard, M, Bieche, I, Poupon, M-F, Bellet, D, Dangles-Marie, V
Publicado 2009

Independent prognostic value of somatic TP53 gene mutations in 1794 breast cancer patients

por Olivier, M, Langerød, A, Carrieri, P, Bergh, J, Klaar, S, Eyfjord, J, Theillet, C, Rodriguez, C, Lidereau, R, Bièche, I, Varley, J, Bignon, Y, Uhrhammer, N, Winqvist, R, Jukkola-Vuorinen, A, Niederacher, D, Kato, S, Ishioka, C, Hainaut, P, Børresen-Dale, A-L
Publicado 2005

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers

por Coussy, F., El Botty, R., Lavigne, M., Gu, C., Fuhrmann, L., Briaux, A., de Koning, L., Dahmani, A., Montaudon, E., Morisset, L., Huguet, L., Sourd, L., Painsec, P., Chateau-Joubert, S., Larcher, T., Vacher, S., Melaabi, S., Salomon, A. Vincent, Marangoni, E., Bieche, I.
Publicado 2020

A refined molecular taxonomy of breast cancer

por Guedj, M, Marisa, L, de Reynies, A, Orsetti, B, Schiappa, R, Bibeau, F, MacGrogan, G, Lerebours, F, Finetti, P, Longy, M, Bertheau, P, Bertrand, F, Bonnet, F, Martin, A L, Feugeas, J P, Bièche, I, Lehmann-Che, J, Lidereau, R, Birnbaum, D, Bertucci, F, de Thé, H, Theillet, C
Publicado 2012